Anti-Inflammatory Effects of Antidepressant Treatments and the Use of Inflammatory Biomarkers in Major Depressive Disorder: A Narrative Review

Anti-Inflammatory Effects of Antidepressant Treatments and the Use of Inflammatory Biomarkers in Major Depressive Disorder: A Narrative Review

ES评分 0

DOI 10.20900/jpbs.20260006
刊名
JPBS
年,卷(期) 2026, 11(3)
作者
作者单位

University Hospital of Psychiatry and Psychotherapy, University of Bern, 3008 Bern, Switzerland

摘要
Major depressive disorder (MDD) has a complex pathophysiology and is one of the leading causes of disability worldwide. Treatment resistant depression (TRD) is associated with significant functional impairment, higher rates of suicidal behavior, and a higher risk of general and psychiatric comorbidities. It is well established that MDD is often associated with elevated levels of peripheral inflammatory markers, leading to neuroinflammation. There is frequent comorbidity of MDD with metabolic disorders, such as obesity and type 2 diabetes. Mounting evidence suggests that obesity is a risk factor for both inflammation and depression, and that white adipose tissue is a potential source of pro-inflammatory cytokines. The development of novel drugs with dual effects on both depression and inflammation would be of great interest for more efficacious and personalized treatment of MDD with underlying inflammatory and metabolic processes. This narrative review aimed to elucidate the impact of neuroinflammation and metabolic abnormalities on MDD pathophysiology. It provides insights into agents targeting inflammatory mechanisms related to MDD, such as nonsteroidal anti-inflammatory pathways, cytokine antagonism, N-methyl-D-aspartate receptor antagonism, modulation of the kynurenine pathway, and glucagon-like peptide-1 receptors. Moreover, this review illustrates the role of potential inflammatory biomarkers in improving TRD prevention and treatment.
Abstract
Major depressive disorder (MDD) has a complex pathophysiology and is one of the leading causes of disability worldwide. Treatment resistant depression (TRD) is associated with significant functional impairment, higher rates of suicidal behavior, and a higher risk of general and psychiatric comorbidities. It is well established that MDD is often associated with elevated levels of peripheral inflammatory markers, leading to neuroinflammation. There is frequent comorbidity of MDD with metabolic disorders, such as obesity and type 2 diabetes. Mounting evidence suggests that obesity is a risk factor for both inflammation and depression, and that white adipose tissue is a potential source of pro-inflammatory cytokines. The development of novel drugs with dual effects on both depression and inflammation would be of great interest for more efficacious and personalized treatment of MDD with underlying inflammatory and metabolic processes. This narrative review aimed to elucidate the impact of neuroinflammation and metabolic abnormalities on MDD pathophysiology. It provides insights into agents targeting inflammatory mechanisms related to MDD, such as nonsteroidal anti-inflammatory pathways, cytokine antagonism, N-methyl-D-aspartate receptor antagonism, modulation of the kynurenine pathway, and glucagon-like peptide-1 receptors. Moreover, this review illustrates the role of potential inflammatory biomarkers in improving TRD prevention and treatment.
关键词
major depressive disorder; neuroinflammation; metabolic disorders; pro-inflammatory cytokines; glucagon like peptide-1 receptor; inflammatory biomarkers
KeyWord
major depressive disorder; neuroinflammation; metabolic disorders; pro-inflammatory cytokines; glucagon like peptide-1 receptor; inflammatory biomarkers
基金项目
页码 -
  • 参考文献
  • 相关文献
  • 引用本文

Sigrid Breit. Anti-Inflammatory Effects of Antidepressant Treatments and the Use of Inflammatory Biomarkers in Major Depressive Disorder: A Narrative Review [J]. Journal of Psychiatry and Brain Science. 2026; 11; (3). - .

  • 文献评论

相关学者

相关机构